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PRECIS
Among gynecologists with no prior training, the initial cases of laparoscopic 
radiofrequency ablation of leiomyomas can be performed with rapid onset of 
surgical confidence and favorable clinical outcomes.
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ABSTRACT
Study Objective 
To assess surgical outcomes, clinical effectiveness, and gynecologist’s experience of 
introducing laparoscopic radiofrequency ablation (RFA) of leiomyomas into surgical 
practice.
Design Uncontrolled clinical trial
Setting 5 academic medical centers across California
Patients 
Premenopausal women with symptomatic uterine leiomyomas, uterus ≤16 week size
and all leiomyomas ≤10 cm with no more than 6 total leiomyomas.
Interventions
Laparoscopic RFA of leiomyomas.
Measurements and Main Results
We assessed intraoperative complications, blood loss, operative time, and adverse 
events. Gynecologists reported the difficulty and need for further training after 
each case. Participants reported leiomyoma symptoms preoperatively and at 6 and
12 weeks after surgery. We analyzed all outcome data from the first case 
performed by gynecologists with no prior RFA experience.
Patient demand for RFA was high, but poor insurance authorization prevented 74% 
of eligible women from trial participation; 26 women underwent surgery and 
enrolled. The mean age of participants was 41.5 years (standard deviation (SD) 
4.9). Mean operating time was 153 minutes (SD 51) and estimated blood loss was 
24cc (SD 40). There were no intraoperative complications and no major adverse 
events. Menstrual bleeding, sexual function, and quality of life symptoms 
improved significantly from baseline to 12 weeks with a 25 point (SD 18), or 47% 
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decrease in the leiomyoma Symptom Severity Score. After the first procedure 
performed, 6 was the mean difficulty score (Confidence Interval (CI) 4, 7.5) on a 10 
point scale and 89% of surgeons felt “very or somewhat” confident in performing 
laparoscopic RFA; the score decreased to 4.25 (CI 1.2, 6) after the fourth procedure
with all gynecologists reporting surgical confidence.
Conclusions
Laparoscopic RFA of leiomyomas can be introduced into surgical practice with good 
clinical outcomes for patients. Gynecologists with no prior experience are able to 
gain confidence and skill with the procedure quickly in <5 cases
Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA)
https://clinicaltrials.gov/ct2/show/NCT01840124
ClinicalTrials.gov Identifier: NCT01840124
Date registered: April 25, 2013
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INTRODUCTION
Uterine leiomyomas occur in up to 80% of premenopausal women and 
are the most common indication for major gynecological surgery in the United 
States. The estimated annual cost of care for women with leiomyomas is $34 
billion, with 50% of the cost from lost work and disability related to surgical 
hospitalization and recovery time.1 Many women with leiomyomas seek new 
minimally invasive uterine-sparing treatments with rapid recovery and durable 
symptom relief that may defray the cost and prolonged disability of traditional 
leiomyoma surgeries. 
Laparoscopic radiofrequency ablation (RFA) of leiomyomas is an 
outpatient, uterine- preserving, minimally invasive surgery that aims to improve
leiomyoma symptoms with minimal operative risks and short recovery time. 
The pivotal trial of RFA to gain Federal Drug Administration (FDA) device 
approval enrolled 134 women and demonstrated significant improvement in 
leiomyoma-related symptoms and a decrease in leiomyoma volume; 11% of 
patients underwent additional leiomyoma surgery at 3 years of follow-up.2 
Although the device for RFA of leiomyomas was FDA approved in November
2012, lack of coverage among major insurance carriers limited the use of this 
procedure during the initial years of market availability.  However, in January 
2017, RFA was assigned a CPT code by the American Medical Association which 
has increased coverage authorization by commercial payers and allowed greater 
uptake of RFA into gynecologic surgical practice. Therefore, there is an urgent 
need to understand the learning curve, surgical outcomes, and clinical 
effectiveness during the start-up phase of gynecologic surgeons adopting this 
new leiomyoma treatment into clinical practice.
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MATERIALS and METHODS
The Uterine Leioleiomyoma Treatment with Radiofrequency Ablation
(ULTRA) trial is an investigator-initiated single-arm  clinical trial of
laparoscopic RFA of uterine leiomyomas. Women were recruited from
September  1,  2013  through December  31,  2015 from patients at five
academic  medical center  sites across California within the  University of
California (UC) health system: UC Davis, UC San Francisco, UC Los Angeles,
UC Irvine, and UC San Diego. The general public was also targeted for
recruitment through social media campaigns,  newspaper ads, and publicly
posted flyers. The study was registered on clinicaltrials.gov (#NCT01840124)
on  April  25,  2013,  approved for  all  UC  sites  by the  UC San Francisco
Institutional Review Board (IRB  number:   13-11026    Approval  Date:
05/02/2013)  and all participants gave written informed consent  for study
enrollment. An independent Data Safety and Monitoring Board (DSMB) of two
gynecologists and one biostatistician not  employed by UC approved the
study protocol and met every 6  months to assess patient safety and data
quality.
Women were eligible to participate if they were 21 years or older, 
premenopausal (at least one period in the last three months), and seeking 
uterine sparing surgical treatment of leiomyomas for heavy bleeding, pelvic 
pressure or discomfort, urinary or bowel symptoms, or dyspareunia. Eligible 
participants had to have undergone a pelvic exam and imaging with ultrasound 
or magnetic resonance imaging (MRI) within the last year to assess leiomyoma 
characteristics. We defined a leiomyoma as any mass on pelvic imaging ≥2cm 
consistent with the typical appearance of a uterine leiomyoma. Women were 
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included if the uterus was ≤16 week size, all leiomyomas ≤10 cm in maximum 
diameter, and they had no more than six leiomyomas. Eligible participants had to
have a negative pregnancy test, normal cervical cancer screening within the 
previous 3 years and, for those over 45 with heavy or irregular bleeding, a 
normal endometrial biopsy. We excluded women if they were planning treatment
for infertility, had need for a concomitant surgical procedure (e.g. hernia repair 
or cystectomy), had pelvic infection within the last three months, had a history 
of pelvic malignancy or radiation, or any implantable metallic device. We also 
excluded women with a high suspicion for dense pelvic adhesions and any 
surgical or procedural treatment for leiomyomas within the last three months. 
We also excluded women with leiomyoma characteristics that are not amenable to
laparoscopic RFA treatment: pedunculated leiomyomas with stalk <25% of the 
maximum leiomyoma diameter, intracavitary leiomyoma (FIGO Type 0), or the 
only leiomyoma is submucosal ≥50% intracavitary (FIGO Type 1). Women who 
desired future fertility were included in the trial after detailed counseling by their 
physician that the treatment is not FDA approved for women who desire future 
pregnancy and there is insufficient data to determine the impact of treatment on 
fertility and pregnancy outcomes. The consent form also listed a possible 
increase in the risk of adverse pregnancy outcomes including miscarriage, 
placental abnormalities, uterine rupture, and fetal demise. The treating physician
also discussed the risks and benefits of all other leiomyoma treatment options 
including all medical and procedural therapies available at their clinical site. 
At the time of study enrollment, laparoscopic RFA of leiomyomas was a 
new procedure with unknown coverage among commercial insurance 
companies. Therefore, after all women interested in laparoscopic RFA were 
screened for eligibility and counseled about the risks and benefits of surgery 
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and the availability of other leiomyoma treatments, we sent a request for 
surgery preauthorization to their insurance carrier.  If coverage was denied, we 
presented interested women the opportunity to undergo an appeal process with
their insurance carrier. If authorization for coverage was received, a surgery 
date was scheduled to undergo the procedure and the patient completed 
informed consent and was enrolled in the study.
The laparoscopic RFA procedures were performed at each site by an 
attending gynecologist with assistance from a resident physician. The seven 
treating gynecologic surgeons underwent a one day didactic and surgical 
simulation training course provided by the RFA device manufacturer.  For the 
first five procedures performed by each gynecologist, a physician trainer and a 
device technician were present in the operating room to answer questions and 
provide guidance, but did not scrub into the cases. There were no run-in 
procedures for the trial; we collected data on safety and effectiveness 
beginning with the first case performed. None of the treating gynecologists had 
previous experience with intraoperative ultrasound or use of radiofrequency 
energy to treat leiomyomas or any other condition. All surgeons were general 
gynecologists except one who had completed an advanced fellowship in 
minimally invasive gynecologic surgery.
The gynecologic surgeons performed all RFA procedures under general 
anesthesia using standard sterile laparoscopic technique. A single-toothed 
tenaculum was placed on the anterior lip of the cervix for uterine manipulation 
and then the patient was placed in the dorsal supine position. The surgeon 
placed dispersive electrode pads designed specifically for the RFA procedure 
(AcessaTM) on each thigh 1cm superior to the patella after wiping the area with 
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an alcohol swipe. A 5mm laparoscope was placed at the umbilicus and a 10mm 
port was placed at the uterine fundus for the rigid laparoscopic ultrasound 
transducer. The surgeons then surveyed the entire uterus by ultrasound to 
measure and document the visualized leiomyomas.
The RFA device (AcessaTM) is a 3.4mm disposable handpiece with an 
electrode array that consists of 7 deployable needles to deliver radiofrequency 
energy from an external generator (Figure 1). The surgeon can control the 
radiofrequency energy delivered through the handpiece and monitor the 
temperature surrounding each needle during treatment on a monitor connected
to the generator. To treat each leiomyoma, the surgeon placed the handpiece in
the pelvis through a small stab incision and passed it through the uterine 
serosa to deploy it into the leiomyoma tissue using ultrasound guidance. After 
correct needle array placement was verified, the duration of treatment for each 
leiomyoma was determined by its size using an algorithm that aims to treat the 
entire leiomyoma volume within 1cm of the leiomyoma capsule. A continuous, 
alternating current with a maximum output of 200W was used during each 
deployment to bring the leiomyoma temperature to 950C. For larger 
leiomyomas, multiple passes were needed to complete a full ablation. Monopolar
coagulation was then used to create hemostasis along the track of the 
handpiece as it is removed from the uterus. After all leiomyomas were treated, 
the surgeon closed the skin incisions with standard laparoscopic procedures 
according to standard local practice.  All procedures were planned as outpatient 
surgeries.
The primary outcome for ULTRA was change in leiomyoma symptoms 
measured by the Uterine Leiomyoma Symptoms-Quality of Life (UFS-QOL) 
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questionnaire3 from baseline to 6 and 12 weeks following treatment. We used 
additional self-reported questionnaires to assess change in other leiomyoma- 
related symptoms including: 1) the Menstrual Impact Questionnaire (MIQ) for 
heavy bleeding4, 2) the Short Form Health Survey (SF-36) for quality of life5,6,  3)
and the Sexual Outcomes in Women Questionnaire (SHOW-Q) for sexual 
function.7 We collected data on operative outcomes including surgery duration, 
estimated blood loss, and complications. Immediately following the procedure, 
each attending gynecologist rated the difficulty of the procedure on a scale 
from 0 to 10 and whether they would be comfortable performing the surgery 
without assistance from a device manufacturer representative in the operating 
room.
Participants reported postoperative outcomes during phone and on-line 
interviews at 2 days and 1, 3, 6, and 12 weeks following surgery. Participants 
received gift cards of $20 after completing the baseline and 6 week 
questionnaires. To assess postoperative recovery, we asked participants to rate 
their post-operative pain on a scale from 0 to 10, to report their use of pain 
medication, and when they returned to their usual activities and/or work. We 
queried participants about pre-specified adverse events (infection of the 
incision, urinary tract, or uterus, deep vein thrombosis, blood transfusion, 
incisional hernia, or abnormal vaginal discharge) as well as unanticipated 
complications (“Have there been any other adverse changes to your health that 
impacted your ability to perform your normal activities or resulted in an 
unplanned or unscheduled doctor visit?”). 
We assessed changes from baseline to follow-up time points using t tests 
for means and chi-squared for proportions. Assuming a 5% type 1 error and 
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90% power, the initial sample size was set at 100 participants with the aim of 
collecting data on the first 20 cases at each of the 5 clinical sites. In addition, 
with 100 participants, we could detect a minimal change of 7.2 in the UFS-QOL 
from baseline to 12 weeks. This is a clinically significant change because 
meaningful improvements in quality of life are generally felt to occur with a 
minimum 10 point change in the UFS-QOL. However, the study investigators 
faced significant unanticipated challenges in gaining commercial insurance 
authorization to perform the surgery despite frequent appeals to a diverse 
range of payers. Therefore, after two years, the DSMB and study investigators 
decided to close study enrollment because the target sample size would not be 
reached during the specified, funded recruitment timeframe.
RESULTS
Across all five study sites, there were 783 women screened for study 
participation (Figure 2). After counseling about the procedure, including the 
potential for insurance companies to deny authorization for coverage and the 
long wait times to manage appeals to insurance coverage decisions, 210 (27%) 
of these women elected to undergo other leiomyoma treatment. Lack of any 
insurance coverage or a carrier that was accepted at our study sites excluded 
225 (29%) of women; 229 (29%) were deemed ineligible based on clinical 
inclusion criteria such as pregnancy, menopause status, a large leiomyoma size
and/or number. One hundred ten women were eligible and agreed to undergo 
the RFA surgery; 70 (64%) were denied insurance coverage. Although 40 (36%)
women ultimately gained insurance approval for coverage, 14 (13%) decided 
not to undergo surgery because substantial time had passed and symptoms had
improved spontaneously or with medical management. Twenty-six women 
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gained insurance approval, enrolled in the study, and underwent the RFA 
treatment.
The study population was racially and ethnically diverse with a mean age
of 41.5 years (Table 1). Most of the  participants (46%) worked full time  and
19% were covered by Medicaid. The mean uterine size by bimanual exam was
12 weeks (standard deviation (SD) 2.6) with an average of two leiomyomas
(SD 1.2) , a total leiomyoma volume of 150cc (SD 114), and the mean diameter
of the largest leiomyoma of 5.6cm (SD 1.6cm). At the time of study enrollment,
24% of participants reported prior leiomyoma surgery and 38% were using
medication  to  control  leiomyoma symptoms.  Leiomyoma symptoms had a
significant impact on all activities of study participants with 38% reporting they
had taken time  off work due to leiomyomas and 77% reporting that  they
avoided their usual activities due to menstrual symptoms. 
The RFA surgery had a low average blood loss of 24 cc (SD 40) and a 
mean operative (skin to skin) time of 153 minutes (Table 2, SD 51). All 
procedures were completed successfully with no intraoperative complications or 
conversion to laparotomy. Attending gynecologists gained comfort with the 
procedure quickly (Figure 3). After four cases, 50% of treating surgeons 
reported that they felt comfortable performing the procedure without assistance
from a company trainer in the operating room. Confidence in performing the 
procedure was also high with 100% of gynecologists reporting that they felt 
somewhat or very confident in performing the procedure after 4 cases. On a 
scale from 0 to 10, the mean difficulty rating by gynecologists after the first 
case was 6 (SD 2.35) and decreased each case to a nadir of 4.25 (SD 2.22) 
after four cases.
Postoperative recovery was, on average, less than two weeks (Figure 4). 
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Two days after surgery, the mean pain score was 3.7 (95% CI 2.97,4.47) and 
56% of participants were using opoid pain medication. Pain scores decreased 
over the next several weeks with a nadir of 1.0 (95% CI 0.42,1.57) at the 3 
week follow-up when no participants reported using pain medication. The 
average time taken off of work was 10.8 days (SD 7.1) and return to usual 
activities was 9.2 days (SD6.5). Five days after surgery, 34% of participants 
were back to their usual activities and 50% had returned to work with an 
increase to 69% return to usual activities and 73% returned to work by 10 days 
after surgery.
In the 6 weeks following surgery, there were no major adverse events 
(Table 3). During follow up, one participant reported abnormal vaginal 
discharge and two had urinary tract infections three or more weeks after 
surgery. Participants reported a wide range of minor symptoms including 
gastrointestinal events (bloating, constipation, pain), fatigue, sore throat, 
musculoskeletal pain, and rash, most of which were reported within the first 
week following surgery. Overall, 8 (32%) participants reported at least one 
minor adverse event at the 2 day and 1 week visit. 
Leiomyoma-related symptoms significantly improved from baseline to 6 
and 12 weeks after surgery (Table 4). UFS-QOL symptom scores improved by 25
points at 12 weeks (p<0.01) a corresponding increase in quality of life scores by
22 points (P<0.01). All of the domains in the Menstrual Impact Questionnaire 
improved significantly 12 weeks after treatment including the overall report of 
menstrual blood loss and the impact of menstrual bleeding on work and 
physical and social activities. At 12 weeks, the average score for all domains 
that measure bleeding impact was 1 which indicates no impact of menstrual 
bleeding on quality of life. Sexual health also improved in several domains after 
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treatment with a decrease in the mean score for reporting that pelvic problems 
interfere with sex, increased sexual desire, and improved satisfaction with sex 
12 weeks after treatment. Overall quality of life also improved in the Physical 
Component Scale of the SF-36 at 12 weeks but not the Mental Component Scale.
At 6 and 12 weeks of follow-up, no participants reported use of medications to 
control leiomyoma symptoms or any new leiomyoma procedures or surgeries. 
DISCUSSION
In this analysis of the ULTRA study, we report key clinical outcomes and 
operator experience during the initial adoption of laparoscopic RFA into 
leiomyoma surgical practice. A prior study of 40 RFA cases during the “run-in” 
period of a randomized trial reported surgeon experience, but gynecologists 
were only assessed after they “felt comfortable” with the procedure, had 
completed 2-5 cases, and could complete the procedure “safely”.8   In contrast, 
our trial includes surgical outcomes beginning with the very first case completed
among gynecologists with no prior experience using RFA. Therefore, we provide 
a unique opportunity to assess the learning curve and clinical outcomes during 
the initial cases completed. These results serve to guide and inform 
gynecologists considering adopting this new surgical treatment and improve 
patient counseling about the risks and benefits as it is introduced into practice.
The learning curve for new surgical techniques has garnered much 
attention in the last fifteen years as new minimally invasive laparoscopic 
surgical techniques have grown in popularity and availability. For laparoscopic 
hysterectomy, 25-40 completed cases is reported as the threshold to reach 
surgical proficiency.9-13 Newer techniques such as robot-assistance with 
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laparoscopic hysterectomy or single-port laparoscopic myomectomy have also 
been shown to require 45-50 cases to minimize adverse events.14,15 In contrast 
to this high volume of cases, 89% of gynecologists in our study reported being 
somewhat or very confident in performing the procedure after the very first 
case of RFA. This confidence level rose to 100% of gynecologists after four 
procedures, when half of the surgeons felt they no longer required the physician
trainer in the operating room. After the first case, gynecologists reported that 
the procedure was moderately difficult with a score of 6.0 (SD 2.35), but the 
score dropped quickly to 4.25 (SD 2.22) by the fourth case. RFA for 
leiomyomas does not require laparoscopic suturing; in ULTRA, general 
gynecologists were able to learn the procedure quickly and gain confidence and 
skill in less than five cases.
With the introduction of new surgical techniques, case volume has also 
been linked to operative outcomes and the rate of adverse events. In large case
series of gynecologists learning laparoscopic hysterectomy, the rate of surgical 
complications decreases over time as the volume of cases increases for each 
surgeon.16-18 In the first 26 cases of RFA performed in our trial, there were no 
intra-operative complications, conversions to laparotomy, or serious adverse 
events in the 6 weeks following surgery. However, this is a very small sample 
size that is underpowered to adequately assess surgical complications.
Operative
 time in our trial was 2.5 hours, about 40 minutes longer than 
in the “run-in” phase of 40 cases in a RFA randomized trial (114 min, SD 60 
min).8 The longer operative time in our trial may in part be related to the skill of 
the surgical assistant. At four of our clinical centers, residents in obstetrics and 
gynecology served as surgical assists, while cases in the “run-in” phase of the 
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randomized trial were completed by two attending gynecologists who had both 
completed the RFA training course.8  With a small overall number of cases, our 
trial is underpowered to adequately assess if changes in operative time occur as 
RFA volume increases. However, there were no statistically significant 
differences in the duration of surgery between the 1st and 4th case performed by 
the study gynecologists. We did not query surgeons about what part of the RFA 
procedure most impacts overall operative time. However, surgical time may 
vary by the number, size, and location of leiomyomas to be treated because 
surgeons aim to treat all fibroids during the RFA procedure. The time required to
deliver radiofrequency energy increases as total fibroid tissue volume increases,
either with larger size within one fibroid or higher number of total fibroids. 
Further study is needed to understand how these variables and other factors 
may impact overall operative time.
In addition to safety and ease of performing the surgery, patient-reported
outcomes were favorable during this early use of RFA. Recovery time was 
rapid; 35% of participants had returned to work 2 days after surgery and 73% 
by 10 days. At baseline, study participants were highly symptomatic, but by 12 
weeks after surgery, all patient-reported outcomes had improved significantly 
including overall leiomyoma symptoms, heavy bleeding, and sexual health. The
25 point improvement in the UFS-QOL Symptom Severity score is similar to 
changes in this symptom scale reported in the pivotal trial of laparoscopic 
RFA19, and other trials of uterine-preserving leiomyoma procedures 12 weeks 
after
Treatment.20,21
The ULTRA trial highlights the strong demand for new minimally invasive 
uterine sparing leiomyoma treatments. In a two-year period, 783 women 
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expressed interest in the trial and were screened for study eligibility. Many of 
these women were planning future pregnancy and seeking alternatives to 
myomectomy. Currently, the RFA device has not been approved by the FDA for
women who desire future fertility because of limited pregnancy outcome data. 
The largest case series reported 30 pregnancies in 28 women who had 
undergone RFA of leiomyoma in clinical trials or post-market practice 
settings22, Among these pregnancies, 26 (86.7%) delivered at term with 
healthy infants; 50% by cesarean section and 50% by vaginal delivery. 
Obstetric complications were noted in 2 patients; one had placenta previa and 
one had a post-partum hemorrhage in which she expelled a degenerated 
fibroid per vagina 2 days after cesarean section and required endometrial 
curettage and 6 units of transfused blood. Additional data is needed with much
larger sample size to further evaluate pregnancy outcomes and determine the 
safety of RFA for women who seek future fertility. 
CONCLUSION
Unlike many other new laparoscopic procedures, our results suggest that 
laparoscopic RFA may be adopted quickly into leiomyoma surgical practice. 
Although the sample size is small, we found statistically significant 
improvements in leiomyoma-related symptoms from baseline to 6 and 12 
weeks following surgery, even in the initial cases performed by each provider. 
Since the close of the trial, a new visual guidance system has been introduced 
to assist gynecologists in correctly targeting the RF probe into the leiomyoma. 
This support may further decrease the difficulty score, even after the first 
procedure. One limitation of the study is the single-arm unblinded design which 
may bias patient-reported outcomes such as changes in leiomyoma symptoms, 
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but   is unlikely to have an effect on surgeon difficulty rating or the rate of 
complications. Future studies should focus on comparative effectiveness 
studies to provide more definitive conclusions about how RFA outcomes 
compared with other available leiomyoma surgeries and procedures.
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Figure 1 Legend. Laparoscopic Radiofrequency Ablation of Uterine Leiomyoma
Figure 2 Legend. Screening and Enrollment of Study Participants
Figure 3 Legend. Gynecologist Rating of Surgical Difficulty
Figure 4 Legend. Post-Operative Recovery Measure
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Table 1. Baseline Characteristics
                                                                                                
Total N=26 
                                                                                                
Number (%) 
                                                                                                
or 
 Characteristic                                                             
Mean (SD)
Demographic Characteristics
Age, MeanSD 41.54.9
Race/Ethnicity
Asian 1 (4)
Black/African American 6 (23)
Latina/Hispanic 4 (15)
White 15 (58)
Other 4 (15)
Education
<=High School 2 (8)
College Degree or more 19 (73)
Some College 5 (19)
Employment
Full time 12 (46)
Homemaker/Child care 4 (15)
Seeking/Other 4 (15)
Part time/Student 7 (27)
Insurance
Medi-Caid 5 (19)
Medicare 1 (4)
Other 2 (8)
Private insurance (HMO or PPO) 18 (69)
Clinical Characteristics
Body mass index         27.0 (4.6)
Parity
0 18 (69)
24
535
536
537
1-2 8 (31)
Current Sexual Partner 21 (81)
Prior leiomyoma surgical treatment 6 (24)
Current use of medication for leiomyoma 
symptoms
10 (38)
Days of Menstrual Bleeding, MeanSD 7.03.7
Days of Heavy Menstrual Bleeding 3.2 (1.9)
Anemia 8 (31)
Had to take time off work due to leiomyomas 10 (38)
Avoids usual activities due to heavy menses 20 (77)
Use hormonal treatments for leiomyoma 
symptoms
6 (23)
Leiomyoma Characteristics
Uterine Size (in weeks) 12.02.6
Number of Leiomyomas 2.01.2
Largest leiomyoma diameter (cm) 5.6 (1.6)
Leiomyoma Volume (in cc) 150.2114.0
25
Table 2. Intraoperative Outcomes
Characteristic
Total 
N=26 
(%)Total Operating room time (minutes) 21154
Operating Time (minutes)--skin to skin 15351
Blood loss (cc) 2440
RF ablation completed 100 (100)
Intraoperative Complications 0 (0)
26
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Table 3. Post-Operative Adverse Events
Number (% of Subjects*)
Adverse Event
Day 2 
Visit 
(n=25)
Week
1
Visit
(n=25
Week
3
Visit
(n=26
6
Week
Posto
p
VisitPre-Specified†
Abnormal vaginal discharge 1 (4.0) 1 (4.0) 1 (3.8) 1 (3.8)
Bladder/kidney infection 1 (3.8) 1 (3.8)
Skin infection 1 (4.0)
Gastrointestinal disorders
Abdominal pain 1 (4.0)
Bloating 1 (4.0) 1 (4.0)
Constipation 1 (4.0) 1 (4.0)
Intestinal inflammation 1 (4.0)
General disorders
Fatigue 1 (4.0)
Flu-like symptoms 1 (4.0)
Infections and infestations
Sinus infection 1 (4.0)
Mouth and throat disorders
Gums sore 1 (4.0)
Sore throat 2 (8.0)
Swollen throat gland 1 (4.0)
Musculoskeletal and connective 
tissue disorders
Arthritis 1 (4.0)
Chest/rib cage pain 1 (3.8)
Pain in both arms (elbow joint) 1 (3.8)
Nervous system disorders
Migraine 1 (4.0) 1 (3.8)
Renal and urinary disorders
Urethra soreness 1 (4.0)
Urinary retention 1 (4.0)
27
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Number 
(%
of 
Subjects*)
Adverse Event
Day 2 
Visit 
(n=25)
Week
1
Visit
(n=25
Week
3
Visit
(n=26
6
Week
Posto
p
VisitUrinary urgency 1 (4.0)
Reproductive system
Ovarian cyst
Postop vaginal bleeding 1 (4.0) 1 (4.0)
Uterine cramping 1 (4.0) 1 (3.8)
Skin and subcutaneous tissue 
disordersAdhesive irritation 1 (4.0)
Belly button bleeding 1 (4.0)
Rash 1 (4.0)
Skin blister 1 (4.0)
Skin irritation 1 (4.0)
Skin irritation at site of incision 1 (3.8)
Subjects with 1 or more event 8 (32.0) 8 (32.0) 3 (11.5) 3 (11.5)
*Percent based on the total number of subjects indicated (n); for each column, 
each AE or AE group is counted only once per subject.
†Includes: Infection of skin at incision; infection of bladder or kidneys; infection of 
uterus; blood transfusion; pulmonary embolus or deep vein thrombosis; abnormal 
vaginal discharge; skin burn on leg at site of grounding pad; injury to superficial 
blood vessels; injury to bowel or GI tract; injury to bladder, ureter, or urethra; injury 
to pelvic abdominal blood vessels; problems with intubation or ventilation.
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Table 4. Changes in leiomyoma related symptoms from baseline to 6 and 12 weeks
Score Baseline 6 Week
Change over
6 weeks P-value 12 Week
Change over 
12 weeks P-value
The Uterine Leiomyoma Symptom and Quality of Life (UFS-QoL) scores
Symptom Severity 53.73±20.4
1
42.43±13.7
8
-11.30±17.10 <.01 27.25±15.2
4
-25.13±17.83 <.0001
Quality of Life 50.06±24.1
0
63.95±23.1
2
13.89±18.51 <.01 73.43±20.9
2
22.51±23.86 <.0001
Menorrhagia Impact Questionnaire (MIQ)
Blood Loss* 3.12±0.71 2.81±0.94 -0.31±0.97 0.1060 2.40±0.71 -0.68±0.95 <.01
Limit Work† 2.69±1.52 2.08±1.20 -0.62±1.50 0.0596 1.60±0.71 -1.04±1.49 <.01
Limit Physical Activity† 3.00±1.44 2.35±1.20 -0.65±1.50 <.05 1.80±0.58 -1.12±1.33 <.01
Limit Social Activity† 2.77±1.45 1.92±1.13 -0.85±1.26 <.01 1.60±0.76 -1.08±1.26 <.01
Sexual Health Outcomes in Women Questionnaire (SHOW-Q) scores ‡
Orgasm frequency 
and quality
65.32±24.6
5
66.28±28.8
3
-2.83±32.56 0.9868 72.26±22.9
9
3.78±21.32 0.5314
Pelvic problem 
interference with sex
56.52±33.9
9
30.33±28.4
5
-25.00±28.65 <.01 19.79±23.4
2
-33.33±29.43 <.0001
Sexual desire or interest 43.23±26.6
6
49.67±32.5
9
6.77±25.80 0.2687 53.47±30.3
4
11.05±24.48 <.05
Satisfaction with sex 35.94±19.6
1
52.50±25.7
7
17.71±28.77 <.01 56.25±30.6
2
21.20±34.63 <.01
Short Form Health Survey (SF-36)
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Score Baseline 6 Week
Change over 6 
weeks P-value 12 Week
Change over 
12 weeks P-value
Mental Component Scale 45.83±8.70 49.60±8.04 3.78±7.21 <.05 48.41±10.52 2.05±11.41 0.1620
Physical Component Scale 46.57±9.30 49.16±8.42 2.59±7.53 <.05 52.52±8.94 5.51±7.84 <.01
*Scores on the Menorrhagia Impact Questionnaire blood loss domain scale range from 1 to 4; higher scores indicate greater blood
loss.
†Scores on each of the Menorrhagia Impact Questionnaire domain scales range from 1 to 5; higher scores indicate greater 
limitation on work, physical activities, and social activities, respectively.
‡Scores on each of the Sexual Health Outcomes in Women Questionnaire domain scales range from 0 to 100; higher scores 
indicate greater pelvic problem interference, orgasm frequency and quality, sexual desire or interest, and satisfaction with sex, 
respectively.
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